IBBR Seminar Series
Mass spectrometry plays an important role at every stage of biopharmaceutical development. With the advancement of modern instrumentations, collecting high-quality data becomes routine, while translating data into results becomes the new bottleneck. This presentation describes a battery of computational methods we have developed over the past 20 years to extract information from LC-MS/MS data, together with a few real-world applications.
As a research team embedded within a large casework laboratory, we aim to develop methods that advance forensic casework. This can be by providing investigative leads, by increasing evidential value, or by answering novel forensic questions. Examples of innovations and the perspectives for casework will be presented.
Emerging zoonotic viral diseases have become a major threat to human health and global economy. In this seminar, I will first present our effort in fighting COVID-19 and the finding of multiple organ tropisms and server disease model of SARS-CoV-2 infection of hACE2 transgenic mice. I will then present our data on the origins and evolution of HIV-1 virulence using a hu-BLT mice experimental approach as well as our progress on the HIV transmission, vaccine development and cure.
All living things are subject to attack by viruses. Cells have evolved many different immune systems to protect themselves, including the adaptive and innate immune systems of vertebrates and the CRISPR and restriction:modification systems of bacteria. Viruses have developed potent countermeasures to subvert these systems, and this perpetual arms race has been a strong driving force in evolution throughout the history of life on Earth. The CRISPR system is an adaptive immune system in prokaryotes. Type III CRISPR systems confer a complex, multi-layered defence against viruses.
Pichia pastoris is a methylotrophic yeast that has been used in the production of recombinant proteins for more than 30 years. As a eukaryotic microbial host, P. pastoris is the best of both worlds. It has ability to perform complex post-translational modifications, but grows rapidly to high cell densities using low-cost substrates. In this talk, I will discuss the efforts of our group to improve the production therapeutic proteins and recombinant vaccines in P.